Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference

October 13, 2026

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Performance

52-Week Range 69.1% below 52-week high

0.7487

0.7252W Low 2.4252W High

1 Week 12.6% below 1-week high

0.721W Low 0.861W High

Metagenomi Therapeutics, Inc. - Common Stock (MGX) traded between $0.72 and $2.42 over the past 52 weeks and last traded at $0.75, 69.1% below its 52-week high. Over the past week it ranged between $0.72 and $0.86.

Past 12 Months

-9.8%

-28.0%

-38.4%

-47.6%

-55.2%

-67.3%

1W -$0.08

1M -$0.29

3M -$0.47

6M -$0.68

YTD -$0.92

1Y -$1.54

MGX was -67.3% over the past year, -47.6% over six months, -55.2% year to date, -9.8% in the last week.

12 Months vs Market

MGX

-67.3%

DIA

+10.2%

SPY

+9.7%

QQQ

+6.1%

IWM

+13.3%

Over the past 12 months MGX returned -67.3% versus DIA (Dow) +10.2%, SPY (S&P 500) +9.7%, QQQ (Nasdaq 100) +6.1% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 0.43× 3-mo avg

Today 64,339 3-mo avg 151.2K

93.3K

161.1K

151.2K

164.3K

YTD

191.7K

224.9K

MGX most recently traded 64,339 shares against a 3-month average daily volume of 151.2K.

More News

September 01, 2026

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

August 10, 2026

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026

From ProLynx Inc.

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

May 28, 2026

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 11, 2026

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

April 16, 2026

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

March 05, 2026

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

February 23, 2026

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

January 12, 2026

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

December 01, 2025

Metagenomi to Present at Jefferies Global Healthcare Conference in London

November 17, 2025

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 12, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 11, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 11, 2025

Via Benzinga

November 11, 2025

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

November 11, 2025

Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected ↗

August 12, 2025

Via Chartmill

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

August 12, 2025

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

August 11, 2025